• TrialsWest opens third clinical trial site in Mandurah, WA
• New site expected to open in August, providing significant additional service capacity
• Near term growth expected from participant recruitment for current major pharma trial

Resonance Health Limited (ASX: RHT) is pleased to announce further expansion of the TrialsWest business with the expected August 2025 opening of a third TrialsWest trial site in Mandurah, Western Australia. The new Mandurah Site is ~72km south of Perth, and ~60km from the nearest TrialsWest site located in the Perth suburb of Spearwood. The addition of the Mandurah Site significantly increases the business's participant capacity and enables the Resonance Health group to further capitalise on its existing clinical trial workflows, most notably the major pharma clinical trials being managed by the group. The City of Mandurah is one of the fastest growing cities in Australia, with a 91% growth in population over the past 20 years, equating to an additional 30,000 residents. It is the second most populous city in Western Australia with a population of approximately 105,000 people. The Mandurah Site is the next step in Resonance Health's expansion strategy for TrialsWest and is consistent with the aspirations communicated at the time of TrialsWest's acquisition by Resonance Health. This strategy is focused on delivering growth from a diverse spread of pharma customers and trials over multiple years. The addition of this new site is also consistent with targeting new clinical trial sites in affordable densely populated areas with good transport, car parking and accessibility links, and with low establishment costs.

The addition of the Mandurah Site is expected to provide significant additional service capacity and enable the Resonance Health group to further capitalize on its existing clinical trial workflows, most notably the major pharma clinical trials being managed by the group. Further new sites will be targeted in coming periods along with complementary acquisitions.